MXD3 and urinary bladder carcinoma: In contrast, higher MXD3 expression was associated with clinical benefits in bladder cancer patients to PD-L1 ICB and hence exhibited higher survival durations than bladder cancer cohorts that had lower MXD3 expression levels.